✦ LIBER ✦

Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance

✍ Scribed by Kobelt, G.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMS22 ADALIMUMAB, ETANERCEPT AND INFLIXI

✍ T Macioch; M Niewada; W Wrona; D Golicki; T Hermanowski 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

PMS16 ADALIMUMAB, ETANERCEPT AND INFLIXI

✍ T Macioch; M Niewada; W Wrona; D Golicki; T Hermanowski 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

The cost‐effectiveness of infliximab in

✍ Kobelt, G.; Sobocki, P.; Mulero, J.; Gratacos, J.; Collantes‐Estevez, E.; Braun, 📂 Article 📅 2008 🏛 Informa plc 🌐 English ⚖ 377 KB

PMS15 COST-EFFECTIVENESS OF THE TREATMEN

✍ E Mucino; R Rivas; L Zapata 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

PSS14 COST-EFFECTIVENESS OF THE TREATMEN

✍ E Muciño; R Rivas; L Zapata 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Treatment persistence with adalimumab, e

✍ Boxiong Tang; Mirza Rahman; Heidi C. Waters; Peter Callegari 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 765 KB